{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:32:22Z","timestamp":1794061942511,"version":"4.8.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,11,15]]},"DOI":"10.2169\/internalmedicine.6410-20","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T22:07:28Z","timestamp":1622844448000},"page":"3593-3598","source":"Crossref","is-referenced-by-count":15,"title":["Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer"],"prefix":"10.2169","volume":"60","author":[{"given":"Ryota","family":"Ushio","sequence":"first","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miyasaka","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kanaoka","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Tamura","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Izawa","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hirama","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Teranishi","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Manabe","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Otolaryngology, Head and Neck Surgery Department, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Endocrinology Diabetes and Metabolism Department, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kudo","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.","DOI":"10.1038\/nrc3239"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27: 450-461, 2015.","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168: 707-723, 2017.","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hodi FS, O&apos;Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.","DOI":"10.1056\/NEJMx100063"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.","DOI":"10.1056\/NEJMoa1200690"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.","DOI":"10.1056\/NEJMoa1200694"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62: 132-137, 2016.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"9. Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small-cell lung cancer treated with nivolumab. Lung Cancer 115: 71-74, 2018.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4: 374-378, 2018.","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Teraoka S, Fujimoto D, Morimoto T, et al. Early immune-related adverse events and association with outcome in advanced non-small-cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 12: 1798-1805, 2017.","DOI":"10.1016\/j.jtho.2017.08.022"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Caillat-Zucman S. Molecular mechanisms of HLA association with autoimmune diseases. Tissue Antigens 73: 1-8, 2009.","DOI":"10.1111\/j.1399-0039.2008.01167.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Davis JL, Mittal KK, Freidlin V, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology 97: 1137-1142, 1990.","DOI":"10.1016\/S0161-6420(90)32446-6"},{"key":"14","unstructured":"14. Islam S, Numaga J, Fujino Y, et al. HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 35: 3890-3896, 1994."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Concha del R\u00edo LE, Arellanes-Garc\u00eda L. Vogt-Koyanagi-Harada disease in the developing world. Int Ophthalmol Clin 50: 189-199, 2010.","DOI":"10.1097\/IIO.0b013e3181d26a6f"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada&apos;s disease by PCR-RFLP and the strong association with <i>DRB1* 0405<\/i> and <i>DRB1* 0410<\/i>. Br J Ophthalmol 78: 223-226, 1994.","DOI":"10.1136\/bjo.78.3.223"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 56: 522-529, 2000.","DOI":"10.1034\/j.1399-0039.2000.560606.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 20: 1-6, 2020.","DOI":"10.1186\/s12886-020-01519-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 44: 975-976, 2017.","DOI":"10.1111\/1346-8138.13612"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5: 694-700, 2017.","DOI":"10.1002\/ccr3.911"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fujimura T, Kambayashi Y, Tanita K, et al. <i>HLA-DRB 1* 04: 05<\/i> in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol 45: 735-737, 2018.","DOI":"10.1111\/1346-8138.14273"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wang W, Lam W-C, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 68: 85-95, 2019.","DOI":"10.1007\/s00262-018-2260-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 10: 67-74, 2019.","DOI":"10.1159\/000496682"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/22\/60_6410-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T03:23:30Z","timestamp":1637378610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/22\/60_6410-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":23,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6410-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"article-number":"6410-20"}}